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Abstract
Environmental and genetic factors may modify or contribute to the phenotypic differences observed in multigenic and
monogenic diseases, such as cystic fibrosis (CF). An analysis of modifier genes can be helpful for estimating patient
prognosis and directing preventive care. The aim of this study is to determine the association between seven genetic
variants of four modifier genes and CF by comparing their corresponding allelic and genotypic frequencies in CF patients
(n = 81) and control subjects (n = 104). Genetic variants of MBL2 exon 1 (A, B, C and D), the IL-8 promoter (2251 A/T), the
TNFa promoter (TNF1/TNF2), and SERPINA1 (PI*Z and PI*S) were tested in CF patients and control subjects from
northeastern Mexico by PCR-RFLP.
Results: The TNF2 allele (P = 0.012, OR 3.43, 95% CI 1.25–9.38) was significantly associated with CF under the dominant and
additive models but was not associated with CF under the recessive model. This association remained statistically significant
after adjusting for multiple tests using the Bonferroni correction (P = 0.0482). The other tested variants and genotypes did
not show any association with the disease.
Conclusion: An analysis of seven genetic variants of four modifier genes showed that one variant, the TNF2 allele, appears
to be significantly associated with CF in Mexican patients.
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Introduction
Gene-environment and gene-gene interactions play a role in the
phenotypic expression of genetic diseases in individuals harboring
the same genotype [1]. Cystic fibrosis (CF) has an estimated
incidence of one in 3000 in the Caucasian population, although its
frequency may vary in specific subgroups. A newborn screening
study conducted in Mexico City revealed two CF-affected
newborns among 7193 screened (1:3597) participants, suggesting
a high frequency of CF among Mexicans [2]. Approximately 1900
mutations and variants have been reported in the CF transmem-
brane conductance regulator (CFTR) gene, with DF508 being the
most prevalent mutation (50%–60%, http://www.genet.sickkids.
on.ca/app). CF primarily involves epithelial cells in the respiratory
tract, intestine, pancreas, bladder, and sweat glands; respiratory
failure, however, is the major cause of death in CF patients [3].
Variants in genes that are involved in the inflammatory
response have been studied in CF patients based on their potential
effects on inflammation and host defense mechanisms. The
mannose binding lectin (MBL2) gene encodes a serum acute-
phase protein secreted by the liver, resembling the complement
component C1q, that leads to opsonization and activation of the
complement system through the classical pathway [4]. The serum
concentration and complement-triggering activity of MBL depend
on single-base mutations in the MBL2 gene [5–7]. These
mutations may increase the susceptibility of carriers to coloniza-
tion by bacterial and viral pathogens [8]. The best known genetic
variants in exon 1 of the MBL2 gene are Gly54Asp (the B allele,
rs1800450), Gly57Glu (the C allele, rs1800451) and Arg52Cys (the
D allele, rs5030737), which are together referred to as the O allele.
The interleukin 8 (IL-8) gene codes for a member of the CXC
chemokine family and is mainly involved in the initiation and
amplification of acute inflammatory reactions [9]. IL-8 is
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produced by a wide range of cell types, such as monocytes,
macrophages, and fibroblasts; it primarily mediates the activation
and migration of neutrophils from peripheral blood into pathogen-
infected tissue, initiating and amplifying inflammatory processes
[10]. A polymorphism in position 2251 of the IL-8 gene (rs4073)
is associated with increased IL-8 expression [11–12]. The tumor
necrosis factor alpha (TNFa) gene expresses a multifunctional pro-
inflammatory cytokine secreted in response to numerous specific
stimuli, such as lipopolysaccharides. This molecule induces the
release of cytokines IL-6 and IL-8 and increases airway mucus
production [13–14]. The 2308 A TNFa promoter polymorphism
(TNF2, rs1800629) has been associated with increased TNFa
transcription activity relative to the normal TNF1 allele (2308 G)
[15–17]. The Alpha-1-antitrypsin (AAT, SERPINA1) gene codes
for an acute-phase serine protease glycoprotein that limits tissue
self-damage during the inflammatory immune response. AAT
deficiency, caused by the S (p.E264V, rs17580) and Z (p.E342K,
rs28929474) alleles in the SERPINA1 gene, may induce liver and
pulmonary disease [18]. Severe AAT deficiency is a co-dominant
autosomal hereditary disorder that clinically resembles early onset
pulmonary emphysema, particularly in smokers [19].
In our Cystic fibrosis clinic, we have a broad range of severity of
the CF disease, even with patients carrying the same genotype. No
reports on variations in modifier genes in Mexican CF patients
have been previously published. Our goal was to explore
polymorphisms in genes related to host defense in healthy controls
and CF patients from northeastern Mexico to find differences in
allelic distribution between both groups. In this study, we report
the genotype and allele frequencies of seven genetic variants in
four previously reported CF modifier genes: MBL, IL-8, TNFa
and AAT.
Materials and Methods
Biological Samples
The study was approved by the Research and Ethics Committee
of the Universidad Autonoma de Nuevo Leon University Hospital
(Registry number BI09-003). After signing written informed
consent, blood samples were drawn from 81 CF patients attending
the Chronic Lung Disease Prevention and Rehabilitation Center
(CEPREP, in Spanish) and from control subjects recruited from
the University Hospital and School of Medicine (Universidad
Autonoma de Nuevo Leon). Also we collected blood samples from
104 control subjects that met the following inclusion criteria: they
agreed to informed consent, they were born in northeastern
Mexico (the states of Nuevo Leon, Tamaulipas, Coahuila, and San
Luis Potosi), and they belonged to a family with at least three
ascending Mexican generations. Genomic DNA was isolated from
peripheral venous blood using the phenol–chloroform method,
precipitated in ethanol, and finally suspended in Tris-EDTA
(pH 7.8).
Screening for the CFTR Gene Mutations
Mutation screening was performed according to the availability
of resources and kits along the time. For previously screened CF
patients: direct detection of DF508 mutation, and Roche ASO16
and 27 mutations kits, for new CF patients: direct detection of
DF508 mutation, INNOLiPA CFTR36 probe kit and Exon
Table 1. Mutations included in the kits used for the molecular diagnosis of CF patients.
Kit Detected mutations
ASO16 Roche DF508, G542X, G551D, R553X, W1282X, N1303K, R117H, 621+1G .T, R334W, R347P, A455E, DI507, 1717-1G .A, S549N, R560T,
3849+10Kb C .T
ASO26 Roche DF508, G542X, G551D, R553X, W1282X, N1303K, R117H, 621+1G .T, R334W, R347P, A455E, DI507, 1717-1G .A, R560T,
3849+10KbC.T, G85E, 2307insA, G480C, A559T, R1162X, 3659delC, S1255X, R347H, 2789+5G.A, 405+3 A.C, 3120+1G.A
INNOLiPA CFTR36
Innogenetics
F508del, G542X, G551D, R553X, W1282X, N1303K, R117H, 621+1G.T, R334W, R347P, A455E, I507del, 1717-1G.A, R560T,
3849+10KbC.T, G85E, R1162X, 3659delC, 2789+5G.A, 3120+1G.A, 711+1G.T, 3905insT, S1251N, Q552X, I148T, 1898+1G.A,
394delTT, 1078delT, 2183AA.G, 2184delA, E60X, 2143delT, 711+5G.A, 3199del6, 3272-26A.G, dele2,3
doi:10.1371/journal.pone.0090945.t001
Table 2. Modifier genes analysis by PCR-RFLP adapted from previously published techniques [21–24].
Gene Polymorphism Primers Enzyme Mutant allele, bp Normal allele, bp
MBL Arg52Cys (D) F: CAT CAA CGG CTT CCC AGG GCA AGA TGG G Mwo I 134 109+25
Gly54Asp (B) R: GTC TCC TCA TAT CCC CAG GC Ban I 134 95+39
Gly57Glu (C) Mbo II 78+56 134
IL-8 2251 T/A F: GAT TCT GCT CTT ATG CCT CCA Mfe I 816 520+296
R: CCC AAG CTT GTG TGC TCT GCT GTC
TNFa 2308 G/A F: GGG ACA CAC AAG CAT CAA GG Nco I 142 126+16
R: AAT AGG TTT TGA GGG CCA TG
AAT PI*S Glu264Val F: GAG GGG AAA CTA CAG CAC CTC G Taq Ia 98 78+20
R: ACC CTC AGG TTG GGG AAT CAC C
PI*Z Glu342Lys F: TAA GGC TGT GCT GAC CAT CGT C Taq Ia 144 123+21
R: GGA GAC TTG GTA TTT TGT TCA ATC
doi:10.1371/journal.pone.0090945.t002
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11-specific PCR and sequencing. Short descriptions of the
methodologies are presented below.
PCR and electrophoresis to detect the DF508 mutation: PCR
product was analyzed in polyachrylamide gels and the diagnosis
was established comparing to molecular marker and DNAs of
previously DF508 diagnosed patients and control subjects (98 bp
band for normal allele or 95 bp band for DF508 mutation) [20].
Roche ASO16 and 27 kits (Roche Molecular Systems, Alameda
CA, USA) or the INNOLiPA CFTR36 probe kit (Innogenetics,
Ghent, Belgium). Methodology consisted of multiplex PCR
reactions with biotinylated primers. After verifying the amplifica-
tion in an agarose gel of 2%, the products were hybridized to
membrane bound probes. A positive result was expressed as the
appearance of a purple band. Both kits detected normal and
mutated versions to report homozygous or heterozygous status for
the CF patients. Complete list of mutations is shown in Table 1.
Exon 11- specific PCR and sequencing. Exon 11 PCR fragment
was amplified and sequenced in one patient with absence of
hybridization of PCR product on the normal and mutated versions
of the G551D probe in the CFTR36 probe kit.
Modifier Genes Analysis
DNA from CF patients and control subjects was tested for the
Gly54Asp (B allele, rs1800450), Gly57Glu (C allele, rs1800451),
Arg52Cys (D allele, rs5030737), and A (wild type) alleles in exon 1
of the MBL2 gene; the 2251 T/A (rs4073) allele of the IL-8 gene;
the 2308 G/A (TNF1/2, rs1800629) alleles of the TNFa gene;
and the PI*S Glu264Val (rs17580), PI*Z Glu342Lys (rs28929474),
and PI*M (wild type) alleles of the SERPINA1 gene. PCR-RFLP
protocols were adapted from previously reported methods. More
details are explained in Table 2 and Figure 1 [21–24].
Statistical Analysis
The SNP & Variation Suite (SVS) 7 (Golden Helix Inc.,
Bozeman, MA, USA) software program was used to perform all
statistical analyses. The association between the tested genotypes
Figure 1. PCR-RFLP for the modifier genes analysis. 1A: the 134 bp PCR product from exon 1 of the MBL1 gene was digested with Mwo I, Ban I
and Mbo II for detection of polymorphisms in the 52, 54 and 57 codons. 1B: the 816 bp PCR product from promoter region of the IL-8 gene was
digested with Mfe I for detection of the2251 polymorphism. 1C: the 142 bp PCR product from promoter region of the TNFa gene was digested with
Nco I for detection of the2308 polymorphism (TNF2); the 98 bp PCR product from the SERPINA1 gene was digested with Taq Ia for detection of the S
genetic variant; the 144 bp PCR product from the SERPINA1 gene was digested with Taq Ia enzyme for detection of the Z genetic variant. Mw1 is the
molecular marker pBs+Msp I, Mw2 is the molecular marker l+Pst I. PMBL, PIL8, PTNF, PAATS and PAATZ are undigested PCR products. The Z allele was not
detected.
doi:10.1371/journal.pone.0090945.g001
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and CF was analyzed by correlation/trend and chi-squared (x2)
tests under three different models (dominant, recessive, and
additive) and was confirmed with the Bonferroni correction to
detect the false discovery rate. Odds ratios were estimated within
95% confidence intervals. Values of P,0.05 were considered
statistically significant. The Hardy–Weinberg Equilibrium (HWE)
P-values were assessed using a chi-square test.
Results
Eighty-one CF patients and 104 control subjects were recruited
for this study. Genotype frequencies for the CFTR gene are
described in Table 3. A complete genotype characterization was
achieved in 55.6% (n = 45) of the CF patients; in 39.5% (n = 32) of
the CF patients, only one mutation was identified, and in 4.9%
(n = 4) of the CF patients, both mutations remained undetected.
The most prevalent genotypes were DF508/other (46.9%, n = 38)
and DF508/DF508 (35.8%, n = 29). The overall frequency of the
DF508 allele among CF patients was 59.3%. Ten additional
mutations were detected: G542X (4.9%), S549N (3.1%),
2789+5G.A (2.5%), 3849+10 kb (1.9%), G85E, R1162X,
I148T, R334W, DI507, and L206W (0.6% each one). Mutations
in the CFTR gene were not detected in 24.7% of the total CFTR
alleles.
The PCR-RFLP patterns of the seven genetic variants in the
four modifier genes are shown in the Figure 1. The Z allele, and
the homozygote TNF2 and AATS genotypes were not found. The
genotype frequencies of modifier genes in CF patients and control
subjects are shown in Table 4. The B, C, and D alleles of the
MBL2 gene were grouped together and reported as the O allele.
The polymorphisms were in Hardy-Weinberg equilibrium. The
frequencies of the mutant alleles for CF patients and controls were:
the MBL-O allele 0.231 and 0.233, the IL-8 -251T allele 0.576
and 0.569, AATS allele 0.012 and 0.014, and TNF2 allele 0.087
and 0.029, respectively. The TNF2 allele (P= 0.012, Odds Ratio
(OR) 3.43, 95% CI 1.25–9.38) was significantly associated with CF
patients using the dominant model. This association remains
statistically significant after adjusting for multiple testing using the
Bonferroni correction (P= 0.0482). The association value and the
OR of the TNF2 allele were statistically significant when assessed
using the additive model (Dd vs. dd) but not the recessive model
(Table 5). The other genetic variants tested did not show any
association.
Discussion
In the present study, the DF508 mutation accounted for 59.3%
of the mutated CFTR alleles, a frequency that resembles the
mutation frequencies of European Mediterranean countries. In
this regard, this work may be comparable with modifier genes
studies performed in those countries. Two previous CFTR
mutation reports in the Mexican population showed DF508
frequencies of 40.72% [25], 45% [26] and 44.6% [27]. Differences
could be explained by the clinical criteria, geographic origin and
the analytical methods available at that time. The Spanish
federation reported a frequency of 45%. Previous studies in the
Hispanic population reported a DF508 allele frequency ranging
from 29 to 46% [28–30]. The frequencies of the G542X, R1162X
and R334W alleles reflect the Spanish heritage in the Mexican
population, but the S549N and 2789+5 G.A alleles are not
among the most frequent in Spain [31–32]. In this study we
previously detected homozygote S549N and DF508/S549N
genotypes with the ASO16 kit. A second patient was detected by
exon 11 direct sequencing because she presented an abnormal
pattern of the INNOLiPA CFTR36 kit with the normal and
mutant G551D probes. This kit along with the ASO27 excluded
the S549N mutation from the mutation panel, hindering the
CFTR molecular diagnosis in our population. CFTR gene
sequencing should be performed for new or rare CFTR mutations
in Mexican population as S549N, and those mutations obtained
from central Mexico patients (P750L, 846delT, 4160insGGGG
and 297–1 G.A) [25], as well as for those mutations that
remained undetected. It is necessary to establish an adequate
diagnosis strategy based in Mexican genetic profile, considering
that available commercial kits are designed mainly for Caucasian
mutations profile.
In northeastern Mexico, medical care for CF patients is offered
at the Cystic Fibrosis Clinic of the CEPREP (http://www.ceprep.
edu.mx). Since 1987, approximately 200 patients have been
diagnosed with CF based on clinical and molecular analyses. Once
the diagnosis of CF is established, the rate of adherence to medical
treatment and long-term medical monitoring is low, making
investigations into the genetic and environmental factors that
influence the outcome in CF Mexican patients difficult.
In this study, we analyzed seven variants in four modifier genes
previously reported in CF patients and we found an association
between CF and the TNF2 allele.
The proinflammatory role of the TNF2 allele has been
demonstrated in B cell line cultures, where the TNF2 allele was
more potent transcriptional activator compared to the normal
TNF1 [17]. TNF2 allele has been implicated as a potent
immunomediator and pro-inflammatory cytokine in the patho-
genesis of several human diseases, including pulmonary diseases as
CF and asthma. Patients with genotypes related to higher TNFa
production had increased frequency of asthma [33]. In Mexican
population TNF2 allele was found in 6.0% of asthmatic compared
to 2.9% of the controls [34]. These results are similar that those we
found in our study (2.9% for controls and 8.9% for CF patients).
Table 3. CFTR genotype frequencies from 81 Mexican CF
patients.
Genotype N %
DF508/DF508 29 35.8
DF508/X 26 32.1
DF508/G542X 5 6.2
DF508/3849+10 kb 3 3.7
S549N/S549N 2 2.5
G542X/X 2 2.5
DF508/S549N 1 1.2
DF508/L206W 1 1.2
DF508/2789+5G.A 1 1.2
DF508/G85E 1 1.2
2789+5G.A/2789+5G.A 1 1.2
G542X/R1162X 1 1.2
2789+5G.A/X 1 1.2
DI507/X 1 1.2
I148T/X 1 1.2
R334W/X 1 1.2
X/X 4 4.9
Total 81 100
X: unknown allele.
doi:10.1371/journal.pone.0090945.t003
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By the other hand, recent studies in Mexican population reported
a higher frequency of the TNF2 allele in healthy unrelated
Mexican individuals (7.3%) [35]. Another report related TNF2
allele to breast cancer in Mexican patients compared to healthy
women (7.5 and 24.5% respectively) [36]. Differences in TNF1
allele frequency in control subjects could be explained by sample
size, methodology and characteristics of the studied group. Our
study included population from Northeastern Mexico, while the
other studies had different criteria as gender, living in Mexico City
or been born in Mexico.
Previous studies in CF patients have shown that TNF2 is
associated with a lower percentage of predicted forced expiratory
volume in one second (FEV1) and weight z scores [37]. In Mexican
population, the TNF2 allele has been associated with rheumatoid
arthritis [38], geriatric lipid profile [39] and spondyloarthritis [40].
This variant has also been reported to be associated with obesity
and asthma [41–42]. The high frequency of the TNF2 allele in
Mexican CF patients could suggest a heterozygote advantage. In
Colombia, an inverse association between the TNF polymorphism
and autoimmunity and TB has been reported; this association
suggests the existence of a heterozygote advantage and is
consistent with the hypothesis that autoimmune diseases are a
consequence of natural selection for enhanced TB resistance [43–
44].
MBL2, IL-8 and AAT did not show an association with the CF
genotype. MBL2 had previously shown associations with different
disturbances in the lung function, infection risk, and survival of CF
patients [6,45–48]. In asthma, MBL has been associated with
Chlamydia pneumoniae–specific IgG and a greater risk of developing
asthma, especially in children with chronic or recurrent infection
[49]. MBL levels in asthmatic children positively correlate with
peripheral blood eosinophils [50]. MBL therapy may be useful in
MBL-deficient patients; it may reduce the susceptibility to or
enhance the recovery from bacterial infection or modify the
natural history of the disease [51–53]. The IL-8 2251 polymor-
phism has been associated with CF lung disease severity and the
differential expression of IL-8, suggesting that the IL-8 variant
modifies CF lung disease severity [54]. The2251 variant has been
associated with asthma, infection by respiratory syncytial virus,
and chronic obstructive pulmonary disease (COPD) [10,55–56].
Finally, despite the association between AAT deficiency and
COPD, studies of AAT variants and infection in CF patients have
been inconclusive [57–60]. The incidence of AAT deficiency for
all five phenotypic classes of the Pi*S and Pi*Z deficiency alleles is
1 in 9.8 for Canada and 1 in 11.3 for the United States. However,
a previous report from our group showed very low allele
frequencies of Pi*S and Pi*Z variants in a Mexican population
(1.5% and 0%, respectively) [61].
In summary, the frequencies of genetic variants in the MBL2,
IL-8, and AAT genes of CF patients did not show significant
differences when compared to control subjects, but the TNF2
Table 4. Modifier gene genotype frequencies (%) in CF patients and control subjects; OR, Hardy–Weinberg Equilibrium (HWE) and
results of the association test with Dominant Model P-values.
Gene Genotypes
Genotype
Frequency in
CF Patients
HWE P in
CF Patients
Genotype
Frequency in
Controls
HWE P in
Controls
OR (95% CI)
Dominant Model
P-Value
Dominant Model
N (%) N (%) X2 X2 Bonf. P
MBL2 AA 46 (57.5) 0.4210 63 (61.2) 0.1843 A 1.01 (0.62–1.65) 0.6163 1.0000
AO 31 (38.8) 32 (31.1) O 0.99 (0.61–1.61)
OO 3 (3.8) 8 (7.8)
IL-8 AA 13 (16.5) 0.5786 19 (18.6) 0.9937 T 1.03 (0.68.1.57) 0.9194 1.0000
AT 41 (51.9) 50 (49.0) A 0.97 (0.64–1.48)
TT 25 (31.6) 33 (32.4)
TNFa TNF1/TNF1 66 (82.5) 0.3911 97 (94.2) 0.7608 aTNF1 0.30 (0.11–0.80) 0.0120 0.0482
TNF1/TNF2 14 (17.5) 6 (5.8) bTNF2 3.43 (1.25–9.38)
TNF2/TNF2 0 (0.0) 0 (0)
AAT MM 79 (97.5) 0.9104 101 (97.1) 0.8814 M 1.17 (0.19–7.01) 0.8627 1.0000
MS 2 (2.5) 3 (2.9) S 0.85 (0.14–5.17)
M/Z, S/Z, S/S, Z/Z 0 (0) 0 (0)
CF, cystic fibrosis; OR, Odds Ratio; CI, confidence interval.
aTNF1 2308 G: (dd) vs. (DD, Dd),
bTNF2 2308 A: (DD, Dd) vs. (dd).
HW-P: P-value for the Hardy-Weinberg equilibrium.
X2 Bonf. P = Chi squared test with a Bonferroni-corrected P-value.
doi:10.1371/journal.pone.0090945.t004
Table 5. TNF1/TNF2 association values using dominant,
additive and recessive models.
Model TNFa 2308 G/2308 A OR1 (95% CI) P-value
Dominant TNF1 = 0.29 (0.11–0.79) 0.0122 0.0483
TNF2 = 3.43 (1.25–9.38)
Additive TNF1 = NA 0.0124 0.0493
TNF2 = 3.429 (1.25–9.38)
Recessive NA NA NA
1odds ratio.
2Chi-Squared P.
3Bonf. P.
4Correl/Trend P.
doi:10.1371/journal.pone.0090945.t005
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allele was significantly associated with CF patients. More studies
are needed to identify the role of inflammatory mediators in the
pathophysiology of CF, as emphasized in previous studies. This
information is relevant because clinical trials of drugs targeting
TNFa activity [62] have shown outstanding efficacy in treating
chronic inflammatory diseases.
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